Genrate a flow chart expaining the complications of diabeties
Generating Image
A detailed medical flowchart showing the complications of diabetes mellitus. The chart starts with "Diabetes Mellitus" at the top center as the root node, then branches into two main categories: "Type 1 Diabetes" and "Type 2 Diabetes" feeding into a central "Chronic Hyperglycemia" box. From "Chronic Hyperglycemia", the chart splits into two major pathways: "Microvascular Complications" and "Macrovascular Complications", plus a third branch for "Acute Complications". Microvascular branch includes: Diabetic Retinopathy (leading to Blindness), Diabetic Nephropathy (leading to Chronic Kidney Disease and End-Stage Renal Disease), Diabetic Neuropathy (splitting into Peripheral Neuropathy causing foot ulcers and amputations, and Autonomic Neuropathy causing gastroparesis, orthostatic hypotension, and sexual dysfunction). Macrovascular branch includes: Coronary Artery Disease (leading to Heart Attack/MI), Cerebrovascular Disease (leading to Stroke), Peripheral Arterial Disease (leading to Limb Ischemia and Amputation). Acute Complications branch includes: Diabetic Ketoacidosis (DKA) in Type 1, Hyperosmolar Hyperglycemic State (HHS) in Type 2, and Hypoglycemia from treatment. Each node is a rounded rectangle with color coding: blue for main categories, red for acute complications, orange for macrovascular, purple for microvascular. Arrows connect all nodes clearly. Clean white background, professional medical diagram style with legible labels.
Here is a flowchart covering the major complications of diabetes. Here's a quick summary of what it shows:
Starting Point: Diabetes Mellitus (Type 1 or Type 2) leads to chronic hyperglycemia, which drives all downstream complications.
Three main branches:
1. Microvascular Complications (small vessel damage)
- Retinopathy - damage to retinal blood vessels, can lead to blindness
- Nephropathy - kidney damage, progressing to chronic kidney disease (CKD) and end-stage renal disease (ESRD)
- Neuropathy - nerve damage, split into:
- Peripheral: foot ulcers, Charcot joint, amputations
- Autonomic: gastroparesis, orthostatic hypotension, sexual dysfunction
2. Macrovascular Complications (large vessel disease)
- Coronary Artery Disease - myocardial infarction (heart attack)
- Cerebrovascular Disease - stroke, TIA
- Peripheral Arterial Disease - limb ischemia, gangrene, amputation
3. Acute Complications
- DKA (Diabetic Ketoacidosis) - primarily Type 1
- HHS (Hyperosmolar Hyperglycemic State) - primarily Type 2
- Hypoglycemia - from insulin or medication overdose
The core principle linking all complications is that tight glycemic control (HbA1c targets) significantly reduces the risk of developing both microvascular and macrovascular damage.
Make a presentation abt diabeties
Asking for Preferences
Reading File
Reading File
Running Command
ls /home/daytona/workspace/ 2>/dev/null && mkdir -p /home/daytona/workspace/diabetes-pptx
Writing File
~/diabetes-pptx/create_pptx.js
const pptxgen = require("pptxgenjs");
const pres = new pptxgen();
pres.layout = "LAYOUT_16x9";
pres.title = "Diabetes Mellitus - Clinical Overview";
pres.author = "Medical Education";
// ── Color Palette ──────────────────────────────────────────────
const BG_DARK = "0D2B45"; // deep navy (title / section slides)
const BG_LIGHT = "F4F7FB"; // pale blue-white (content slides)
const ACCENT1 = "1A8FE3"; // bright blue
const ACCENT2 = "E84545"; // red (for acute / danger items)
const ACCENT3 = "27AE60"; // green (management / good)
const TEXT_MAIN = "1B2B3B"; // near-black
const TEXT_LITE = "FFFFFF"; // white
const BORDER = "C5D5E8"; // subtle border
// ══════════════════════════════════════════════════════════════
// SLIDE 1 – TITLE SLIDE
// ══════════════════════════════════════════════════════════════
{
const s = pres.addSlide();
s.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: 10, h: 5.625, fill: { color: BG_DARK } });
// Decorative stripe
s.addShape(pres.ShapeType.rect, { x: 0, y: 3.9, w: 10, h: 0.07, fill: { color: ACCENT1 }, line: { type: "none" } });
// Diabetes icon strip (colored blocks)
for (let i = 0; i < 6; i++) {
s.addShape(pres.ShapeType.rect, {
x: 0 + i * 1.67, y: 0, w: 1.67, h: 0.18,
fill: { color: i % 2 === 0 ? ACCENT1 : "1D6FA4" },
line: { type: "none" }
});
}
s.addText("DIABETES MELLITUS", {
x: 0.5, y: 1.0, w: 9, h: 1.0,
fontSize: 42, bold: true, color: TEXT_LITE, fontFace: "Calibri",
align: "center", charSpacing: 3
});
s.addText("A Clinical Overview for Medical Students & Clinicians", {
x: 0.5, y: 2.2, w: 9, h: 0.6,
fontSize: 18, color: "A8C8E8", fontFace: "Calibri", align: "center", italic: true
});
s.addText("Topics: Definition · Classification · Pathophysiology · Diagnosis\nComplications · Management · Monitoring", {
x: 1, y: 3.0, w: 8, h: 0.7,
fontSize: 13, color: "7FB3D3", fontFace: "Calibri", align: "center"
});
s.addText("June 2026", {
x: 0.5, y: 5.1, w: 9, h: 0.35,
fontSize: 11, color: "5588AA", align: "center"
});
}
// ── Helper: content slide shell ────────────────────────────────
function contentSlide(title, accentColor) {
const s = pres.addSlide();
s.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: 10, h: 5.625, fill: { color: BG_LIGHT }, line: { type: "none" } });
s.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: 10, h: 0.9, fill: { color: accentColor || BG_DARK }, line: { type: "none" } });
s.addText(title, {
x: 0.4, y: 0.1, w: 9.2, h: 0.7,
fontSize: 22, bold: true, color: TEXT_LITE, fontFace: "Calibri", valign: "middle"
});
return s;
}
// ── Helper: card box ───────────────────────────────────────────
function addCard(s, x, y, w, h, header, headerColor, lines) {
s.addShape(pres.ShapeType.rect, { x, y, w, h, fill: { color: "FFFFFF" }, line: { color: BORDER, pt: 1 }, shadow: { type: "outer", color: "CCDDEE", blur: 6, offset: 2, angle: 45, opacity: 0.4 } });
s.addShape(pres.ShapeType.rect, { x, y, w, h: 0.28, fill: { color: headerColor }, line: { type: "none" } });
s.addText(header, { x: x + 0.1, y: y + 0.01, w: w - 0.2, h: 0.28, fontSize: 12, bold: true, color: TEXT_LITE, valign: "middle" });
const items = lines.map((l, i) => ({
text: l,
options: { bullet: { type: "bullet" }, breakLine: i < lines.length - 1, fontSize: 11, color: TEXT_MAIN }
}));
s.addText(items, { x: x + 0.15, y: y + 0.32, w: w - 0.25, h: h - 0.38, fontFace: "Calibri", valign: "top" });
}
// ══════════════════════════════════════════════════════════════
// SLIDE 2 – DEFINITION & EPIDEMIOLOGY
// ══════════════════════════════════════════════════════════════
{
const s = contentSlide("Definition & Epidemiology", BG_DARK);
// Definition box
s.addShape(pres.ShapeType.rect, { x: 0.3, y: 1.05, w: 9.4, h: 0.85, fill: { color: "E8F2FA" }, line: { color: ACCENT1, pt: 1.5 } });
s.addText([
{ text: "Definition: ", options: { bold: true, color: ACCENT1 } },
{ text: "A group of metabolic disorders characterised by chronic hyperglycaemia resulting from defects in insulin secretion, insulin action, or both (WHO).", options: { color: TEXT_MAIN } }
], { x: 0.45, y: 1.1, w: 9.1, h: 0.75, fontSize: 13, fontFace: "Calibri" });
// Stat cards
const stats = [
["537 M", "Adults living with diabetes worldwide (IDF 2021)"],
["~50%", "Cases undiagnosed globally"],
["3rd leading", "Cause of death in many high-income countries"],
["$966 B", "Global health expenditure on diabetes (2021)"]
];
stats.forEach(([big, small], i) => {
const x = 0.3 + i * 2.4;
s.addShape(pres.ShapeType.rect, { x, y: 2.1, w: 2.25, h: 1.35, fill: { color: i % 2 === 0 ? BG_DARK : ACCENT1 }, line: { type: "none" } });
s.addText(big, { x, y: 2.18, w: 2.25, h: 0.65, fontSize: 22, bold: true, color: TEXT_LITE, align: "center", fontFace: "Calibri" });
s.addText(small, { x, y: 2.82, w: 2.25, h: 0.55, fontSize: 10, color: "BBDDEE", align: "center", fontFace: "Calibri" });
});
s.addText("Risk factors: obesity, physical inactivity, family history, age >45, gestational diabetes, hypertension, dyslipidaemia", {
x: 0.3, y: 3.65, w: 9.4, h: 0.55, fontSize: 12, color: TEXT_MAIN, fontFace: "Calibri",
fill: { color: "FEF3CD" }, align: "left", valign: "middle"
});
s.addText("⚠ Risk factors", { x: 0.35, y: 3.67, w: 1.5, h: 0.25, fontSize: 11, bold: true, color: "B7860B" });
}
// ══════════════════════════════════════════════════════════════
// SLIDE 3 – CLASSIFICATION
// ══════════════════════════════════════════════════════════════
{
const s = contentSlide("Classification of Diabetes Mellitus", ACCENT1);
const cards = [
{ header: "Type 1 DM", color: ACCENT2, lines: ["Autoimmune destruction of β-cells", "Absolute insulin deficiency", "Onset: childhood/adolescence", "Prone to DKA", "HLA-DR3/DR4 associated"] },
{ header: "Type 2 DM", color: BG_DARK, lines: ["Insulin resistance + relative deficiency", "~90% of all DM cases", "Onset: usually >40 yrs (now younger)", "Strongly linked to obesity", "Progressive β-cell failure"] },
{ header: "Gestational DM", color: "7D3C98", lines: ["Any degree of glucose intolerance during pregnancy", "Risk: macrosomia, pre-eclampsia", "Screen at 24–28 weeks", "75g OGTT diagnostic", "↑ risk T2DM later in life"] },
{ header: "Other Specific Types", color: "2E86AB", lines: ["MODY (monogenic)", "Pancreatogenic (T3c)", "Drug-induced (steroids, tacrolimus)", "Endocrinopathies (Cushing's, acromegaly)", "Neonatal DM"] }
];
cards.forEach((c, i) => {
const col = i % 2;
const row = Math.floor(i / 2);
addCard(s, 0.25 + col * 4.85, 1.1 + row * 2.2, 4.6, 2.1, c.header, c.color, c.lines);
});
}
// ══════════════════════════════════════════════════════════════
// SLIDE 4 – PATHOPHYSIOLOGY
// ══════════════════════════════════════════════════════════════
{
const s = contentSlide("Pathophysiology", "1D6FA4");
// T1 column
s.addShape(pres.ShapeType.rect, { x: 0.25, y: 1.05, w: 4.35, h: 3.85, fill: { color: "FFF5F5" }, line: { color: ACCENT2, pt: 1 } });
s.addShape(pres.ShapeType.rect, { x: 0.25, y: 1.05, w: 4.35, h: 0.32, fill: { color: ACCENT2 }, line: { type: "none" } });
s.addText("Type 1 – Autoimmune", { x: 0.3, y: 1.06, w: 4.2, h: 0.3, fontSize: 13, bold: true, color: TEXT_LITE });
s.addText([
{ text: "1. Genetic susceptibility (HLA-DR3/DR4)\n", options: { bold: true } },
{ text: "2. Environmental trigger (viral, dietary)\n" },
{ text: "3. Autoantibodies: anti-GAD, anti-IA2, anti-ZnT8\n" },
{ text: "4. CD4+/CD8+ T-cell mediated β-cell destruction\n" },
{ text: "5. >80% β-cell loss → absolute insulin deficiency\n" },
{ text: "6. Glucagon unopposed → DKA risk\n" }
], { x: 0.38, y: 1.42, w: 4.15, h: 3.4, fontSize: 12, fontFace: "Calibri", color: TEXT_MAIN });
// T2 column
s.addShape(pres.ShapeType.rect, { x: 5.0, y: 1.05, w: 4.75, h: 3.85, fill: { color: "F0F8FF" }, line: { color: BG_DARK, pt: 1 } });
s.addShape(pres.ShapeType.rect, { x: 5.0, y: 1.05, w: 4.75, h: 0.32, fill: { color: BG_DARK }, line: { type: "none" } });
s.addText("Type 2 – Metabolic", { x: 5.05, y: 1.06, w: 4.6, h: 0.3, fontSize: 13, bold: true, color: TEXT_LITE });
s.addText([
{ text: "Ominous Octet (DeFronzo):\n", options: { bold: true } },
{ text: "↓ Insulin secretion (β-cell failure)\n" },
{ text: "↑ Hepatic glucose production\n" },
{ text: "↓ Muscle glucose uptake (IR)\n" },
{ text: "↑ Lipolysis → free fatty acids\n" },
{ text: "↑ Glucagon (α-cell dysfunction)\n" },
{ text: "↓ Incretin effect (GIP, GLP-1)\n" },
{ text: "↑ Renal glucose reabsorption (SGLT2 upregulation)\n" },
{ text: "↑ Central appetite dysregulation\n" }
], { x: 5.1, y: 1.42, w: 4.55, h: 3.4, fontSize: 12, fontFace: "Calibri", color: TEXT_MAIN });
}
// ══════════════════════════════════════════════════════════════
// SLIDE 5 – DIAGNOSIS
// ══════════════════════════════════════════════════════════════
{
const s = contentSlide("Diagnosis (ADA / WHO Criteria)", ACCENT1);
// Table header
const cols = [2.2, 2.2, 2.2, 2.4];
const headers = ["Test", "Diabetes", "Pre-diabetes", "Normal"];
const hColors = [BG_DARK, ACCENT2, "E67E22", ACCENT3];
let xPos = 0.2;
headers.forEach((h, i) => {
s.addShape(pres.ShapeType.rect, { x: xPos, y: 1.05, w: cols[i], h: 0.38, fill: { color: hColors[i] }, line: { type: "none" } });
s.addText(h, { x: xPos, y: 1.05, w: cols[i], h: 0.38, fontSize: 13, bold: true, color: TEXT_LITE, align: "center", valign: "middle" });
xPos += cols[i];
});
const rows = [
["Fasting Plasma Glucose", "≥ 7.0 mmol/L\n(126 mg/dL)", "5.6–6.9 mmol/L\n(IFG)", "< 5.6 mmol/L"],
["2-hr 75g OGTT", "≥ 11.1 mmol/L\n(200 mg/dL)", "7.8–11.0 mmol/L\n(IGT)", "< 7.8 mmol/L"],
["HbA1c", "≥ 48 mmol/mol\n(≥ 6.5%)", "39–47 mmol/mol\n(5.7–6.4%)", "< 39 mmol/mol"],
["Random PG + Sx", "≥ 11.1 mmol/L\nwith symptoms", "—", "—"]
];
rows.forEach((row, ri) => {
xPos = 0.2;
const bgColor = ri % 2 === 0 ? "FFFFFF" : "EEF5FB";
row.forEach((cell, ci) => {
s.addShape(pres.ShapeType.rect, { x: xPos, y: 1.43 + ri * 0.72, w: cols[ci], h: 0.72, fill: { color: bgColor }, line: { color: BORDER, pt: 0.5 } });
s.addText(cell, { x: xPos + 0.05, y: 1.43 + ri * 0.72, w: cols[ci] - 0.1, h: 0.72, fontSize: 11.5, color: TEXT_MAIN, align: "center", valign: "middle", fontFace: "Calibri" });
xPos += cols[ci];
});
});
s.addText("Note: In asymptomatic individuals, two abnormal results on separate days are required for diagnosis.", {
x: 0.2, y: 4.45, w: 9.6, h: 0.4, fontSize: 11, italic: true, color: "667788", fontFace: "Calibri"
});
s.addText("Sx = classic symptoms (polyuria, polydipsia, unexplained weight loss) · IFG = Impaired Fasting Glucose · IGT = Impaired Glucose Tolerance", {
x: 0.2, y: 4.85, w: 9.6, h: 0.35, fontSize: 10, color: "889AAA", fontFace: "Calibri"
});
}
// ══════════════════════════════════════════════════════════════
// SLIDE 6 – CLINICAL FEATURES
// ══════════════════════════════════════════════════════════════
{
const s = contentSlide("Clinical Features", "2E86AB");
const items = [
{ label: "Polyuria", detail: "Osmotic diuresis from glucosuria", icon: "💧" },
{ label: "Polydipsia", detail: "Secondary to dehydration & hyperosmolality", icon: "🥤" },
{ label: "Polyphagia", detail: "Cellular starvation despite hyperglycaemia", icon: "🍽️" },
{ label: "Weight loss", detail: "Catabolism (especially T1DM)", icon: "⚖️" },
{ label: "Blurred vision", detail: "Osmotic lens swelling", icon: "👁️" },
{ label: "Fatigue & weakness", detail: "Impaired glucose utilisation", icon: "😴" },
{ label: "Recurrent infections", detail: "Candidiasis, UTIs, skin infections", icon: "🦠" },
{ label: "Slow wound healing", detail: "Impaired neutrophil function & angiogenesis", icon: "🩹" }
];
items.forEach((item, i) => {
const col = i % 2;
const row = Math.floor(i / 2);
const x = 0.25 + col * 4.9;
const y = 1.1 + row * 1.05;
s.addShape(pres.ShapeType.rect, { x, y, w: 4.65, h: 0.9, fill: { color: "FFFFFF" }, line: { color: BORDER, pt: 1 } });
s.addShape(pres.ShapeType.rect, { x, y, w: 0.55, h: 0.9, fill: { color: ACCENT1 }, line: { type: "none" } });
s.addText(item.icon, { x, y, w: 0.55, h: 0.9, fontSize: 20, align: "center", valign: "middle" });
s.addText(item.label, { x: x + 0.62, y: y + 0.06, w: 3.9, h: 0.3, fontSize: 13, bold: true, color: TEXT_MAIN });
s.addText(item.detail, { x: x + 0.62, y: y + 0.38, w: 3.9, h: 0.4, fontSize: 11, color: "556677", fontFace: "Calibri" });
});
}
// ══════════════════════════════════════════════════════════════
// SLIDE 7 – COMPLICATIONS
// ══════════════════════════════════════════════════════════════
{
const s = contentSlide("Complications of Diabetes", ACCENT2);
// Acute
s.addShape(pres.ShapeType.rect, { x: 0.2, y: 1.0, w: 9.6, h: 0.3, fill: { color: ACCENT2 }, line: { type: "none" } });
s.addText("ACUTE COMPLICATIONS", { x: 0.2, y: 1.01, w: 9.6, h: 0.28, fontSize: 12, bold: true, color: TEXT_LITE, align: "center" });
const acute = [
["DKA", "T1DM; pH <7.3, ketones, anion gap ↑"],
["HHS", "T2DM; glucose >33, no ketosis, hyperosmolar"],
["Hypoglycaemia", "BG <4 mmol/L; sweating, tremor, confusion"]
];
acute.forEach(([t, d], i) => {
s.addShape(pres.ShapeType.rect, { x: 0.2 + i * 3.22, y: 1.32, w: 3.12, h: 0.75, fill: { color: "FFF0F0" }, line: { color: ACCENT2, pt: 1 } });
s.addText(t, { x: 0.25 + i * 3.22, y: 1.35, w: 3.0, h: 0.28, fontSize: 13, bold: true, color: ACCENT2 });
s.addText(d, { x: 0.25 + i * 3.22, y: 1.63, w: 3.0, h: 0.4, fontSize: 10.5, color: TEXT_MAIN, fontFace: "Calibri" });
});
// Chronic micro
s.addShape(pres.ShapeType.rect, { x: 0.2, y: 2.2, w: 4.7, h: 0.3, fill: { color: "7D3C98" }, line: { type: "none" } });
s.addText("MICROVASCULAR", { x: 0.2, y: 2.21, w: 4.7, h: 0.28, fontSize: 12, bold: true, color: TEXT_LITE, align: "center" });
addCard(s, 0.2, 2.52, 4.7, 2.65, "Small Vessel Disease", "7D3C98", [
"Retinopathy – leading cause of blindness (working age)",
"Nephropathy – CKD → ESRD (dialysis)",
"Peripheral Neuropathy – foot ulcers, Charcot joint",
"Autonomic Neuropathy – gastroparesis, OH, ED",
"Mechanism: polyol pathway, AGEs, PKC, oxidative stress"
]);
// Chronic macro
s.addShape(pres.ShapeType.rect, { x: 5.1, y: 2.2, w: 4.7, h: 0.3, fill: { color: "1A5276" }, line: { type: "none" } });
s.addText("MACROVASCULAR", { x: 5.1, y: 2.21, w: 4.7, h: 0.28, fontSize: 12, bold: true, color: TEXT_LITE, align: "center" });
addCard(s, 5.1, 2.52, 4.7, 2.65, "Large Vessel Disease", "1A5276", [
"Coronary Artery Disease – MI (2–4× higher risk)",
"Cerebrovascular Disease – stroke / TIA",
"Peripheral Arterial Disease – limb ischaemia, amputation",
"Mechanism: accelerated atherosclerosis, endothelial dysfunction",
"CV disease is the #1 cause of death in T2DM"
]);
}
// ══════════════════════════════════════════════════════════════
// SLIDE 8 – MANAGEMENT
// ══════════════════════════════════════════════════════════════
{
const s = contentSlide("Management Overview", ACCENT3);
// Glycaemic targets bar
s.addShape(pres.ShapeType.rect, { x: 0.2, y: 1.0, w: 9.6, h: 0.5, fill: { color: "E8F8EF" }, line: { color: ACCENT3, pt: 1 } });
s.addText([
{ text: "Glycaemic Targets (ADA 2024): ", options: { bold: true, color: ACCENT3 } },
{ text: "HbA1c <53 mmol/mol (<7.0%) | FPG 4.4–7.2 mmol/L | PPG <10 mmol/L ", options: { color: TEXT_MAIN } }
], { x: 0.35, y: 1.02, w: 9.3, h: 0.46, fontSize: 12, fontFace: "Calibri", valign: "middle" });
// Non-pharmacological
addCard(s, 0.2, 1.62, 3.0, 3.45, "Non-Pharmacological", ACCENT3, [
"MNT: low GI diet, calorie deficit",
"Physical activity: 150 min/wk moderate",
"Weight loss ≥5–10% in T2DM",
"Smoking cessation",
"Alcohol moderation",
"Diabetes self-management education (DSME)",
"BP & lipid control"
]);
// T1 Pharmacology
addCard(s, 3.45, 1.62, 3.0, 3.45, "T1DM Pharmacotherapy", ACCENT2, [
"Basal-bolus insulin regimen",
"Basal: glargine, detemir, degludec",
"Bolus: lispro, aspart, glulisine",
"CSII (insulin pump) option",
"CGM for all T1DM",
"Adjunct: pramlintide (amylin analog)",
"Target TIR >70%"
]);
// T2 Pharmacology
addCard(s, 6.7, 1.62, 3.1, 3.45, "T2DM Pharmacotherapy", BG_DARK, [
"1st line: Metformin + lifestyle",
"Add-on (CV/CKD): SGLT2i or GLP-1 RA",
"SGLT2i: empagliflozin, dapagliflozin",
"GLP-1 RA: semaglutide, dulaglutide",
"DPP-4i, sulfonylureas, TZDs",
"Insulin when HbA1c uncontrolled",
"Consider weight-loss surgery (BMI≥35)"
]);
}
// ══════════════════════════════════════════════════════════════
// SLIDE 9 – MONITORING & TARGETS
// ══════════════════════════════════════════════════════════════
{
const s = contentSlide("Monitoring & Screening", "2E86AB");
const monitors = [
{ title: "HbA1c", freq: "Every 3–6 months", target: "< 53 mmol/mol\n(< 7.0%)", color: ACCENT1 },
{ title: "Blood Pressure", freq: "Every visit", target: "< 130/80 mmHg", color: ACCENT2 },
{ title: "Lipids (LDL-C)", freq: "Annually", target: "< 1.8 mmol/L\n(high CV risk)", color: "E67E22" },
{ title: "Renal function\n(eGFR + ACR)", freq: "Annually", target: "ACR < 3 mg/mmol\neGFR trend", color: "7D3C98" },
{ title: "Eye Exam\n(Fundoscopy)", freq: "Annually", target: "Detect early NPDR", color: BG_DARK },
{ title: "Foot Exam", freq: "Every visit", target: "10-g monofilament\nPeripheral pulses", color: ACCENT3 }
];
monitors.forEach((m, i) => {
const col = i % 3;
const row = Math.floor(i / 3);
const x = 0.22 + col * 3.25;
const y = 1.08 + row * 2.15;
s.addShape(pres.ShapeType.rect, { x, y, w: 3.1, h: 2.05, fill: { color: "FFFFFF" }, line: { color: BORDER, pt: 1 } });
s.addShape(pres.ShapeType.rect, { x, y, w: 3.1, h: 0.35, fill: { color: m.color }, line: { type: "none" } });
s.addText(m.title, { x, y, w: 3.1, h: 0.35, fontSize: 13, bold: true, color: TEXT_LITE, align: "center", valign: "middle" });
s.addText("Frequency:", { x: x + 0.1, y: y + 0.42, w: 2.9, h: 0.25, fontSize: 11, bold: true, color: "556677" });
s.addText(m.freq, { x: x + 0.1, y: y + 0.66, w: 2.9, h: 0.3, fontSize: 12, color: TEXT_MAIN, fontFace: "Calibri" });
s.addText("Target:", { x: x + 0.1, y: y + 1.02, w: 2.9, h: 0.25, fontSize: 11, bold: true, color: "556677" });
s.addText(m.target, { x: x + 0.1, y: y + 1.26, w: 2.9, h: 0.55, fontSize: 12, color: m.color, bold: true, fontFace: "Calibri" });
});
}
// ══════════════════════════════════════════════════════════════
// SLIDE 10 – KEY TAKEAWAYS
// ══════════════════════════════════════════════════════════════
{
const s = pres.addSlide();
s.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: 10, h: 5.625, fill: { color: BG_DARK }, line: { type: "none" } });
s.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: 10, h: 0.07, fill: { color: ACCENT1 }, line: { type: "none" } });
s.addShape(pres.ShapeType.rect, { x: 0, y: 5.555, w: 10, h: 0.07, fill: { color: ACCENT1 }, line: { type: "none" } });
s.addText("Key Takeaways", { x: 0.4, y: 0.18, w: 9.2, h: 0.55, fontSize: 26, bold: true, color: TEXT_LITE, fontFace: "Calibri" });
const points = [
["01", "Early & accurate diagnosis using ADA criteria is the foundation of management.", ACCENT1],
["02", "T2DM treatment now prioritises CV & renal outcomes — SGLT2i and GLP-1 RAs first-line alongside metformin.", "27AE60"],
["03", "Microvascular complications are largely preventable with tight glycaemic control (DCCT/UKPDS evidence).", "E67E22"],
["04", "Macrovascular disease (CAD, stroke, PAD) remains the #1 killer — manage BP, lipids, and antiplatelet therapy.", ACCENT2],
["05", "Regular structured monitoring (HbA1c, eyes, kidneys, feet) enables early intervention and prevents end-organ damage.", "A569C4"]
];
points.forEach(([num, text, color], i) => {
const y = 0.88 + i * 0.88;
s.addShape(pres.ShapeType.rect, { x: 0.3, y, w: 0.5, h: 0.5, fill: { color }, line: { type: "none" } });
s.addText(num, { x: 0.3, y, w: 0.5, h: 0.5, fontSize: 16, bold: true, color: TEXT_LITE, align: "center", valign: "middle" });
s.addText(text, { x: 0.95, y: y + 0.03, w: 8.7, h: 0.5, fontSize: 13.5, color: "D0E8F8", fontFace: "Calibri", valign: "middle" });
});
s.addText("References: ADA Standards of Care 2024 · WHO DM Definition · IDF Diabetes Atlas 10th Ed · DCCT/UKPDS trials", {
x: 0.3, y: 5.25, w: 9.4, h: 0.3, fontSize: 9.5, color: "5588AA", fontFace: "Calibri", align: "center", italic: true
});
}
// ══════════════════════════════════════════════════════════════
// WRITE FILE
// ══════════════════════════════════════════════════════════════
pres.writeFile({ fileName: "/home/daytona/workspace/diabetes-pptx/Diabetes_Mellitus_Clinical_Overview.pptx" })
.then(() => console.log("SUCCESS: Presentation created."))
.catch(e => { console.error("ERROR:", e); process.exit(1); });
Running Command
cd /home/daytona/workspace/diabetes-pptx && node create_pptx.js 2>&1
Your presentation is ready!
Diabetes Mellitus Clinical Overview
Presentation · PPTX
Here's what's inside the 10-slide deck (clinical level, navy/blue color scheme):
| Slide | Content |
|---|---|
| 1 | Title slide |
| 2 | Definition & Epidemiology (IDF stats, risk factors) |
| 3 | Classification - T1, T2, Gestational, Other |
| 4 | Pathophysiology - autoimmune cascade vs. DeFronzo's Ominous Octet |
| 5 | Diagnosis - ADA/WHO criteria table (FPG, OGTT, HbA1c, random PG) |
| 6 | Clinical Features - 8 symptoms with icons and mechanisms |
| 7 | Complications - Acute (DKA, HHS, hypoglycaemia) + Micro vs. Macrovascular |
| 8 | Management - lifestyle, T1DM insulin regimens, T2DM drug hierarchy (SGLT2i, GLP-1 RA) |
| 9 | Monitoring & Targets - HbA1c, BP, lipids, renal, eye, foot |
| 10 | Key Takeaways with references (ADA 2024, DCCT/UKPDS) |
This is a shared conversation. Sign in to Orris to start your own chat.